证券日报网讯嘉事堂9月16日在互动平台回答投资者提问时表示，公司目前聚焦于药品、医疗器械的批 发配送、专业药械物流及医药零售等主营业务，致力于为医疗机构、下游经销商及终端消费者提供高品 质的医药健康产品与服务。公司现有业务包含创新药销售业务。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯嘉事堂9月16日在互动平台回答投资者提问时表示，公司康复业务处于试点阶段，在探索 中积累经验。公司将继续聚焦主责主业，在医药流通过程中推进固链、强链、延链。 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

Group 1 - The company, Jia Shi Tang (002462), clarified on September 5 that it is currently not involved in any retail department store-related business [1]

Core Insights - The company, Jia Shi Tang, reported a significant decline in net profit by 36.24% year-on-year for the first half of 2025, with total revenue decreasing by 24.45% to 9.699 billion yuan [1] - The second quarter of 2025 saw a revenue of 5.021 billion yuan, down 6.94% year-on-year, and a net profit of 611.14 million yuan, down 34.06% year-on-year [1] Financial Performance - Total revenue for the first half of 2025 was 9.699 billion yuan, compared to 12.839 billion yuan in the same period of 2024, reflecting a decrease of 24.45% [1] - The net profit attributable to shareholders was 1.07 billion yuan, down from 1.68 billion yuan in 2024, marking a decline of 36.24% [1] - The gross profit margin improved to 6.32%, an increase of 4.03% year-on-year, while the net profit margin decreased to 1.68%, down 14.88% [1] - Total expenses (selling, administrative, and financial) amounted to 322 million yuan, representing 3.32% of revenue, a decrease of 13.01% year-on-year [1] - Earnings per share fell to 0.37 yuan, down 36.21% from 0.58 yuan in 2024 [1] - Operating cash flow per share increased significantly to 1.55 yuan, a rise of 314.45% year-on-year [1] Asset and Liability Management - Cash and cash equivalents increased by 30.16% to 2.23 billion yuan, indicating a healthy cash position [1] - Accounts receivable decreased by 15.51% to 6.512 billion yuan, suggesting improved collection efficiency [1] - Interest-bearing debt reduced by 18.37% to 2.357 billion yuan, reflecting better debt management [1] Return on Investment - The company's Return on Invested Capital (ROIC) for the previous year was 4.54%, indicating weak capital returns [3] - The historical median ROIC over the past decade was 9.42%, with the lowest recorded ROIC in 2024 at 4.54% [3] - The net profit margin for the previous year was 1.34%, suggesting low added value in products or services [3] Cash Flow and Receivables - The cash flow situation is a concern, with cash assets covering only 69.79% of current liabilities, and the average operating cash flow over the past three years covering only 16.82% of current liabilities [3] - Accounts receivable have reached 4053.3% of profit, indicating potential issues in receivables management [3]

Group 1 - The company, Jiashitang, announced the convening of its 18th meeting of the 7th Board of Directors on August 29, 2025, to review the semi-annual report and summary for 2025 [1] - For the first half of 2025, Jiashitang's revenue composition was as follows: pharmaceutical wholesale accounted for 96.12%, pharmaceutical retail for 3.18%, and pharmaceutical logistics for 0.7% [1]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 9.699 billion yuan, representing a year-on-year decrease of 24.45% [1] - The net profit attributable to shareholders of the listed company was 107 million yuan, down 36.24% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 96.2624 million yuan, a decrease of 9.84% year-on-year [1] - The basic earnings per share were 0.37 yuan [1]

嘉事堂药业股份有限公司 2025 年半年度财务报告 嘉事堂药业股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 嘉事堂药业股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：嘉事堂药业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 2,230,397,130.89 | 2,223,287,855.91 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 140,994.00 | 174,564.00 | | 衍生金融资产 | | | | 应收票据 | 53,432,675.04 | 262,090,013.09 | | 应收账款 | 6,512,371,481.34 | 6,878,398,107.65 | | 应收款项融资 | 1,475,188.42 | 30,787,051.63 | ...

编制单位：嘉事堂药业股份有限公司 单位：万元 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 二零二五年八月二十九日 | 非经营性资金 | | 占用方与上 | 上市公司 | 2024 年期 | 2024 年上半年占 | 2024 年上半年 | 2024 年上半 | 2024 年上半 | 占用 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 占用 | 资金占用方名称 | 市公司的关 | 核算的会 | 初占用资 | 用累计发生金额 | 占用资金的利 | 年偿还累计 | 年期末占用 | 形成 | 占用性质 | | | | 联关系 | 计科目 | 金余额 | （不含利息） | 息（如有） | 发生金额 | 资金余额 | 原因 | | | 控股股东、实际 | | | | | | | | | 不适 | 不适用 | | 控制人及其附 | 无 | 不适用 | 不适用 | 无 | 无 | 无 | 无 | 无 | 用 | | | 属企业 | | | | | | | | | | | | 小计 | - | - | - ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-33 嘉事堂药业股份有限公司 拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 拟续聘会计师事务所：立信会计师事务所（特殊普通合伙） 2. 本次拟续聘会计师事务所的事项符合财政部、国务院国资委、证监会印 发的《国有企业、上市公司选聘会计师事务所管理办法》等有关规定。公司董事 会、董事会审计委员会对本次拟续聘会计师事务所的事项均不存在异议。 一、拟新聘会计师事务所的基本情况 （一）机构信息 1.基本信息 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗潘 序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改制的 特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。 立信是国际会计网络 BDO 的成员所，长期从事证券服务业务，新证券法实施前具 有证券、期货业务许可证，具有 H 股审计资格，并已向美国公众公司会计监督委 员会（PCAOB）注册登记。 截至 2024 年末，立信拥有合伙人 296 名 ...